细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂联合内分泌治疗已成为HR阳性HER-2阴性晚期或转移性乳腺癌的优选治疗方案。但随着 ...

Atirmociclib作为一种CDK4选择性抑制剂，与现有的CDK4/6抑制剂哌柏西利相比，其在结构上对CDK4的亲和力更高，选择性更强。 细胞 ...

临床数据表明，对于cdk4/6i治疗失败后的晚期HR+/HER2-乳腺癌患者，羟氯喹联合大剂量cdk4/6抑制剂哌柏西利（200 mg，每天一次）的 ...

图 1. CSCO 乳腺癌诊疗指南（2024 版） CDK4/6 抑制剂如今已成为激素受体阳性晚期乳腺癌标准一线治疗方案。随着其大幅降价进入医保，这几年临床越 ...

Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing ...

and CDK4" has been published in Genes & Cancer. The MYC gene is a regulatory and proto-oncogenic gene that is overexpressed in the majority of prostate cancers (PCa). Numerous studies have ...

While the global CDK4/6 inhibitor market remains highly competitive, VERZENIO's distinct clinical advantages and ongoing studies could contribute to further market expansion. VERZENIO (abemaciclib ...